Sapporo Medical University

AUTORES: Daniel J Klionsky1745,1749*, Kotb Abdelmohsen840, Akihisa Abe1237, Md Joynal Abedin1762, Hagai Abeliovich425,
\nAbraham Acevedo Arozena789, Hiroaki Adachi1800, Christopher M Adams1669, Peter D Adams57, Khosrow Adeli1981,
\nPeter J Adhihetty1625, Sharon G Adler700, Galila Agam67, Rajesh Agarwal1587, Manish K Aghi1537, Maria Agnello1826,
\nPatrizia Agostinis664, Patricia V Aguilar1960, Julio Aguirre-Ghiso784,786, Edoardo M Airoldi89,422, Slimane Ait-Si-Ali1376,
\nTakahiko Akematsu2010, Emmanuel T Akporiaye1097, Mohamed Al-Rubeai1394, Guillermo M Albaiceta1294,
\nChris Albanese363, Diego Albani561, Matthew L Albert517, Jesus Aldudo128, Hana Alg€ul1164, Mehrdad Alirezaei1198,
\nIraide Alloza642,888, Alexandru Almasan206, Maylin Almonte-Beceril524, Emad S Alnemri1212, Covadonga Alonso544,
\nNihal Altan-Bonnet848, Dario C Altieri1205, Silvia Alvarez1497, Lydia Alvarez-Erviti1395, Sandro Alves107,
\nGiuseppina Amadoro860, Atsuo Amano930, Consuelo Amantini1554, Santiago Ambrosio1458, Ivano Amelio756,
\nAmal O Amer918, Mohamed Amessou2089, Angelika Amon726, Zhenyi An1538, Frank A Anania291, Stig U Andersen6,
\nUsha P Andley2079, Catherine K Andreadi1690, Nathalie Andrieu-Abadie502, Alberto Anel2027, David K Ann58,
\nShailendra Anoopkumar-Dukie388, Manuela Antonioli832,858, Hiroshi Aoki1791, Nadezda Apostolova2007,
\nSaveria Aquila1500, Katia Aquilano1876, Koichi Araki292, Eli Arama2098, Agustin Aranda456, Jun Araya591,
\nAlexandre Arcaro1472, Esperanza Arias26, Hirokazu Arimoto1225, Aileen R Ariosa1749, Jane L Armstrong1930,
\nThierry Arnould1773, Ivica Arsov2120, Katsuhiko Asanuma675, Valerie Askanas1924, Eric Asselin1867, Ryuichiro Atarashi794,
\nSally S Atherton369, Julie D Atkin713, Laura D Attardi1131, Patrick Auberger1787, Georg Auburger379, Laure Aurelian1727,
\nRiccardo Autelli1992, Laura Avagliano1029,1755, Maria Laura Avantaggiati364, Limor Avrahami1166, Suresh Awale1986,
\nNeelam Azad404, Tiziana Bachetti568, Jonathan M Backer28, Dong-Hun Bae1933, Jae-sung Bae677, Ok-Nam Bae409,
\nSoo Han Bae2117, Eric H Baehrecke1729, Seung-Hoon Baek17, Stephen Baghdiguian1368,
\nAgnieszka Bagniewska-Zadworna2, Hua Bai90, Jie Bai667, Xue-Yuan Bai1133, Yannick Bailly884,
\nKithiganahalli Narayanaswamy Balaji473, Walter Balduini2002, Andrea Ballabio316, Rena Balzan1711, Rajkumar Banerjee239,
\nG abor B anhegyi1052, Haijun Bao2109, Benoit Barbeau1363, Maria D Barrachina2007, Esther Barreiro467, Bonnie Bartel997,
\nAlberto Bartolom e222, Diane C Bassham550, Maria Teresa Bassi1046, Robert C Bast Jr1273, Alakananda Basu1798,
\nMaria Teresa Batista1578, Henri Batoko1336, Maurizio Battino970, Kyle Bauckman2085, Bradley L Baumgarner1909,
\nK Ulrich Bayer1594, Rupert Beale1553, Jean-Fran¸cois Beaulieu1360, George R. Beck Jr48,294, Christoph Becker336,
\nJ David Beckham1595, Pierre-Andr e B edard749, Patrick J Bednarski301, Thomas J Begley1135, Christian Behl1419,
\nChristian Behrends757, Georg MN Behrens406, Kevin E Behrns1627, Eloy Bejarano26, Amine Belaid490,
\nFrancesca Belleudi1041, Giovanni B enard497, Guy Berchem706, Daniele Bergamaschi983, Matteo Bergami1401,
\nBen Berkhout1441, Laura Berliocchi714, Am elie Bernard1749, Monique Bernard1354, Francesca Bernassola1880,
\nAnne Bertolotti791, Amanda S Bess272, S ebastien Besteiro1351, Saverio Bettuzzi1828, Savita Bhalla913,
\nShalmoli Bhattacharyya973, Sujit K Bhutia838, Caroline Biagosch1159, Michele Wolfe Bianchi520,1378,1381,
\nMartine Biard-Piechaczyk210, Viktor Billes298, Claudia Bincoletto1314, Baris Bingol350, Sara W Bird1128, Marc Bitoun1112,
\nIvana Bjedov1258, Craig Blackstone843, Lionel Blanc1183, Guillermo A Blanco1496, Heidi Kiil Blomhoff1812,
\nEmilio Boada-Romero1297, Stefan B€ockler1464, Marianne Boes1423, Kathleen Boesze-Battaglia1835, Lawrence H Boise286,287,
\nAlessandra Bolino2063, Andrea Boman693, Paolo Bonaldo1823, Matteo Bordi897, J€urgen Bosch608, Luis M Botana1308,
\nJoelle Botti1375, German Bou1405, Marina Bouch e1038, Marion Bouchecareilh1331, Marie-Jos ee Boucher1901,
\nMichael E Boulton481, Sebastien G Bouret1926, Patricia Boya133, Micha€el Boyer-Guittaut1345, Peter V Bozhkov1141,
\nNathan Brady374, Vania MM Braga469, Claudio Brancolini1997, Gerhard H Braus353, Jos e M Bravo-San Pedro299,393,508,1374,
\nLisa A Brennan322, Emery H Bresnick2022, Patrick Brest490, Dave Bridges1939, Marie-Agn es Bringer124, Marisa Brini1822,
\nGlauber C Brito1311, Bertha Brodin631, Paul S Brookes1872, Eric J Brown352, Karen Brown1690, Hal E Broxmeyer480,
\nAlain Bruhat486,1339, Patricia Chakur Brum1893, John H Brumell446, Nicola Brunetti-Pierri315,1171,
\nRobert J Bryson-Richardson781, Shilpa Buch1777, Alastair M Buchan1819, Hikmet Budak1022, Dmitry V Bulavin118,505,1789,
\nScott J Bultman1792, Geert Bultynck665, Vladimir Bumbasirevic1470, Yan Burelle1356, Robert E Burke216,217,
\nMargit Burmeister1750, Peter B€utikofer1473, Laura Caberlotto1987, Ken Cadwell896, Monika Cahova112, Dongsheng Cai24,
\nJingjing Cai2099, Qian Cai1018, Sara Calatayud2007, Nadine Camougrand1343, Michelangelo Campanella1700,
\nGrant R Campbell1525, Matthew Campbell1249, Silvia Campello556,1876, Robin Candau1769, Isabella Caniggia1983,
\nLavinia Cantoni560, Lizhi Cao116, Allan B Caplan1656, Michele Caraglia1051, Claudio Cardinali1043, Sandra Morais Cardoso1579, Jennifer S Carew208, Laura A Carleton874, Cathleen R Carlin101, Silvia Carloni2002,
\nSven R Carlsson1267, Didac Carmona-Gutierrez1643, Leticia AM Carneiro312, Oliana Carnevali971, Serena Carra1318,
\nAlice Carrier120, Bernadette Carroll900, Caty Casas1324, Josefina Casas1116, Giuliana Cassinelli324, Perrine Castets1462,
\nSusana Castro-Obregon214, Gabriella Cavallini1841, Isabella Ceccherini568, Francesco Cecconi253,555,1884,
\nArthur I Cederbaum459, Valent ın Ce~na199,1281, Simone Cenci1323,2064, Claudia Cerella444, Davide Cervia1996,
\nSilvia Cetrullo1478, Hassan Chaachouay2028, Han-Jung Chae187, Andrei S Chagin634, Chee-Yin Chai626,628,
\nGopal Chakrabarti1502, Georgios Chamilos1601, Edmond YW Chan1142, Matthew TV Chan181, Dhyan Chandra1003,
\nPallavi Chandra548, Chih-Peng Chang818, Raymond Chuen-Chung Chang1653, Ta Yuan Chang345, John C Chatham1434,
\nSaurabh Chatterjee1910, Santosh Chauhan527, Yongsheng Che62, Michael E Cheetham1263, Rajkumar Cheluvappa1783,
\nChun-Jung Chen1153, Gang Chen598,1676, Guang-Chao Chen9, Guoqiang Chen1078, Hongzhuan Chen1077, Jeff W Chen1514,
\nJian-Kang Chen370,371, Min Chen249, Mingzhou Chen2104, Peiwen Chen1823, Qi Chen1674, Quan Chen172,
\nShang-Der Chen138, Si Chen325, Steve S-L Chen10, Wei Chen2125, Wei-Jung Chen829, Wen Qiang Chen979, Wenli Chen1113,
\nXiangmei Chen1133, Yau-Hung Chen1157, Ye-Guang Chen1250, Yin Chen1447, Yingyu Chen953,955, Yongshun Chen2135,
\nYu-Jen Chen712, Yue-Qin Chen1145, Yujie Chen1208, Zhen Chen339, Zhong Chen2123, Alan Cheng1702,
\nChristopher HK Cheng184, Hua Cheng1728, Heesun Cheong814, Sara Cherry1836, Jason Chesney1703,
\nChun Hei Antonio Cheung817, Eric Chevet1359, Hsiang Cheng Chi140, Sung-Gil Chi656, Fulvio Chiacchiera308,
\nHui-Ling Chiang958, Roberto Chiarelli1826, Mario Chiariello235,567,577, Marcello Chieppa835, Lih-Shen Chin290,
\nMario Chiong1285, Gigi NC Chiu878, Dong-Hyung Cho676, Ssang-Goo Cho650, William C Cho982, Yong-Yeon Cho105,
\nYoung-Seok Cho1064, Augustine MK Choi2095, Eui-Ju Choi656, Eun-Kyoung Choi387,400,685, Jayoung Choi1563,
\nMary E Choi2093, Seung-Il Choi2116, Tsui-Fen Chou412, Salem Chouaib395, Divaker Choubey1574, Vinay Choubey1936,
\nKuan-Chih Chow822, Kamal Chowdhury730, Charleen T Chu1856, Tsung-Hsien Chuang827, Taehoon Chun657,
\nHyewon Chung652, Taijoon Chung978, Yuen-Li Chung1194, Yong-Joon Chwae18, Valentina Cianfanelli254,
\nRoberto Ciarcia1775, Iwona A Ciechomska886, Maria Rosa Ciriolo1876, Mara Cirone1042, Sofie Claerhout1694,
\nMichael J Clague1698, Joan Cl aria1457, Peter GH Clarke1687, Robert Clarke361, Emilio Clementi1045,1398, C edric Cleyrat1781,
\nMiriam Cnop1366, Eliana M Coccia574, Tiziana Cocco1459, Patrice Codogno1375, J€orn Coers271, Ezra EW Cohen1533,
\nDavid Colecchia235,567,577, Luisa Coletto25, N uria S Coll123, Emma Colucci-Guyon516, Sergio Comincini1829,
\nMaria Condello578, Katherine L Cook2073, Graham H Coombs1929, Cynthia D Cooper2076, J Mark Cooper1395,
\nIsabelle Coppens601, Maria Tiziana Corasaniti1387, Marco Corazzari485,1884, Ramon Corbalan1566,
\nElisabeth Corcelle-Termeau251, Mario D Cordero1899, Cristina Corral-Ramos1289, Olga Corti507,1109, Andrea Cossarizza1767,
\nPaola Costelli1993, Safia Costes1518, Susan L Cotman721, Ana Coto-Montes946, Sandra Cottet566,1688, Eduardo Couve1301,
\nLori R Covey1015, L Ashley Cowart762, Jeffery S Cox1536, Fraser P Coxon1427, Carolyn B Coyne1846, Mark S Cragg1919,
\nRolf J Craven1679, Tiziana Crepaldi1995, Jose L Crespo1300, Alfredo Criollo1285, Valeria Crippa558, Maria Teresa Cruz1576,
\nAna Maria Cuervo26, Jose M Cuezva1277, Taixing Cui1907, Pedro R Cutillas987, Mark J Czaja27, Maria F Czyzyk-Krzeska1572,
\nRuben K Dagda2068, Uta Dahmen1404, Chunsun Dai800, Wenjie Dai1187, Yun Dai2059, Kevin N Dalby1940,
\nLuisa Dalla Valle1822, Guillaume Dalmasso1340, Marcello D’Amelio557, Markus Damme188, Arlette Darfeuille-Michaud1340,
\nCatherine Dargemont950, Victor M Darley-Usmar1433, Srinivasan Dasarathy205, Biplab Dasgupta202, Srikanta Dash1254,
\nCrispin R Dass242, Hazel Marie Davey8, Lester M Davids1560, David D avila227, Roger J Davis1731, Ted M Dawson604,
\nValina L Dawson606, Paula Daza1898, Jackie de Belleroche470, Paul de Figueiredo1180,1182,
\nRegina Celia Bressan Queiroz de Figueiredo135, Jos e de la Fuente1023, Luisa De Martino1775,
\nAntonella De Matteis1171, Guido RY De Meyer1443, Angelo De Milito631, Mauro De Santi2002,

autophagic responses. Here, we critically discuss current methods of assessing autophagy and the information they can, or cannot, provide. Our ultimate goal is to encourage intellectual and technical innovation in the field.

A critical function of tumor suppressor p53 is the induction of apoptosis in cells exposed to noxious stresses. We report a previously unidentified pro-apoptotic gene, Noxa. Expression of Noxa induction in primary mouse cells exposed to x-ray irradiation was dependent on p53. Noxa encodes a Bcl-2 homology 3 (BH3)-only member of the Bcl-2 family of proteins; this member contains the BH3 region but not other BH domains. When ectopically expressed, Noxa underwent BH3 motif-dependent localization to mitochondria and interacted with anti-apoptotic Bcl-2 family members, resulting in the activation of caspase-9. We also demonstrate that blocking the endogenous Noxa induction results in the suppression of apoptosis. Noxa may thus represent a mediator of p53-dependent apoptosis.

Cardiovascular disease is the leading cause of death worldwide. Advanced insights into disease mechanisms and therapeutic strategies require a deeper understanding of the molecular processes involved in the healthy heart. Knowledge of the full repertoire of cardiac cells and their gene expression profiles is a fundamental first step in this endeavour. Here, using state-of-the-art analyses of large-scale single-cell and single-nucleus transcriptomes, we characterize six anatomical adult heart regions. Our results highlight the cellular heterogeneity of cardiomyocytes, pericytes and fibroblasts, and reveal distinct atrial and ventricular subsets of cells with diverse developmental origins and specialized properties. We define the complexity of the cardiac vasculature and its changes along the arterio-venous axis. In the immune compartment, we identify cardiac-resident macrophages with inflammatory and protective transcriptional signatures. Furthermore, analyses of cell-to-cell interactions highlight different networks of macrophages, fibroblasts and cardiomyocytes between atria and ventricles that are distinct from those of skeletal muscle. Our human cardiac cell atlas improves our understanding of the human heart and provides a valuable reference for future studies.

BACKGROUND: IgG4-related disease (IgG4-RD) is a novel clinical disease entity characterized by elevated serum IgG4 concentration and tumefaction or tissue infiltration by IgG4+ plasma cells. Although IgG4-RD is not rare and is clinically important, its clinical diagnostic criteria have not been established. Comprehensive diagnostic criteria for IgG4-RD, including the involvement of various organs, are intended for the practical use of general physicians and nonspecialists. METHODS: Two IgG4-RD study groups, the Umehara and Okazaki teams, were organized by the Ministry of Health, Labor and Welfare Japan. As IgG4-RD comprises a wide variety of diseases, these groups consist of physicians and researchers in various disciplines, including rheumatology, hematology, gastroenterology, nephrology, pulmonology, ophthalmology, odontology, pathology, statistics, and basic and molecular immunology throughout Japan, with 66 and 56 members of the Umehara and Okazaki teams, respectively. Collaborations of the two study groups involved detailed analyses of clinical symptoms, laboratory results, and biopsy specimens of patients with IgG4-RD, resulting in the establishment of comprehensive diagnostic criteria for IgG4-RD. RESULTS: Although many patients with IgG4-RD have lesions in several organs, either synchronously or metachronously, and the pathological features of each organ differ, consensus has been reached on two diagnostic criteria for IgG4RD: (1) serum IgG4 concentration >135 mg/dl, and (2) >40% of IgG+ plasma cells being IgG4+ and >10 cells/high powered field of biopsy sample. Although the comprehensive diagnostic criteria are not sufficiently sensitive for the diagnosis of type 1 IgG4-related autoimmune pancreatitis (IgG4-related AIP), they are adequately sensitive for IgG4-related Mikulicz's disease (MD) and kidney disease (KD). In addition, the comprehensive diagnostic criteria, combined with organ-specific diagnostic criteria, have increased the sensitivity of diagnosis to 100% for IgG4-related MD, KD, and AIP. CONCLUSION: Our comprehensive diagnostic criteria for IgG4-RD are practically useful for general physicians and nonspecialists.

IgG4-related disease (IgG4-RD) is a novel clinical disease entity characterized by elevated serum IgG4 concentration and tumefaction or tissue infiltration by IgG4+ plasma cells. Although IgG4-RD is not rare and is clinically important, its clinical diagnostic criteria have not been established. Comprehensive diagnostic criteria for IgG4-RD, including the involvement of various organs, are intended for the practical use of general physicians and nonspecialists. Background: IgG4-related disease (IgG4-RD) is a novel clinical disease entity characterized by elevated serum IgG4 concentration and tumefaction or tissue infiltration by IgG4+ plasma cells. Although IgG4-RD is not rare and is clinically important, its clinical diagnostic criteria have not been established. Comprehensive diagnostic criteria for IgG4-RD, including the involvement of various organs, are intended for the practical use of general physicians and nonspecialists. Methods: Two IgG4-RD study groups, the Umehara and Okazaki teams, were organized by the Ministry of Health, Labor and Welfare Japan. As IgG4-RD comprises a wide variety of diseases, these groups consist of physicians and researchers in various disciplines, including rheumatology, hematology, gastroenterology, nephrology, pulmonology, ophthalmology, odontology, pathology, statistics, and basic and molecular immunology throughout Japan, with 66 and 56 members of the Umehara and Okazaki teams, respectively. Collaborations of the two study groups involved detailed analyses of clinical symptoms, laboratory results, and biopsy specimens of patients with IgG4-RD, resulting in the establishment of comprehensive diagnostic criteria for IgG4-RD. Results: Although many patients with IgG4-RD have lesions in several organs, either synchronously or metachronously, and the pathological features of each organ differ, consensus has been reached on two diagnostic criteria for IgG4RD: (1) serum IgG4 concentration >135 mg/dl, and (2) >40% of IgG+ plasma cells being IgG4+ and >10 cells/high powered field of biopsy sample. Although the comprehensive diagnostic criteria are not sufficiently sensitive for the diagnosis of type 1 IgG4-related autoimmune pancreatitis (IgG4-related AIP), they are adequately sensitive for IgG4-related Mikulicz’s disease (MD) and kidney disease (KD). In addition, the comprehensive diagnostic criteria, combined with organ-specific diagnostic criteria, have increased the sensitivity of diagnosis to 100% for IgG4-related MD, KD, and AIP. Conclusion: Our comprehensive diagnostic criteria for IgG4-RD are practically useful for general physicians and nonspecialists.

The American Joint Committee on Cancer/Union Internationale Contre le Cancer (AJCC/UICC) TNM staging system provides the most reliable guidelines for the routine prognostication and treatment of colorectal carcinoma. This traditional tumour staging summarizes data on tumour burden (T), the presence of cancer cells in draining and regional lymph nodes (N) and evidence for distant metastases (M). However, it is now recognized that the clinical outcome can vary significantly among patients within the same stage. The current classification provides limited prognostic information and does not predict response to therapy. Multiple ways to classify cancer and to distinguish different subtypes of colorectal cancer have been proposed, including morphology, cell origin, molecular pathways, mutation status and gene expression-based stratification. These parameters rely on tumour-cell characteristics. Extensive literature has investigated the host immune response against cancer and demonstrated the prognostic impact of the in situ immune cell infiltrate in tumours. A methodology named 'Immunoscore' has been defined to quantify the in situ immune infiltrate. In colorectal cancer, the Immunoscore may add to the significance of the current AJCC/UICC TNM classification, since it has been demonstrated to be a prognostic factor superior to the AJCC/UICC TNM classification. An international consortium has been initiated to validate and promote the Immunoscore in routine clinical settings. The results of this international consortium may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune).

Fanconi anemia (FA) is a rare autosomal recessive cancer susceptibility disorder characterized by cellular hypersensitivity to mitomycin C (MMC). Six FA genes have been cloned, but the gene or genes corresponding to FA subtypes B and D1 remain unidentified. Here we show that cell lines derived from FA-B and FA-D1 patients have biallelic mutations in BRCA2 and express truncated BRCA2 proteins. Functional complementation of FA-D1 fibroblasts with wild-type BRCA2 complementary DNA restores MMC resistance. Our results link the six cloned FA genes with BRCA1 and BRCA2 in a common pathway. Germ-line mutation of genes in this pathway may result in cancer risks similar to those observed in families with BRCA1 or BRCA2 mutations.

A. Khosroshahi, Z. S. Wallace, J. L. Crowe, T. Akamizu, A. Azumi, M. N. Carruthers, S. T. Chari, E. Della-Torre, L. Frulloni, H. Goto, P. A. Hart, T. Kamisawa, S. Kawa, M. Kawano, M. H. Kim, Y. Kodama, K. Kubota, M. M. Lerch, M. L€ ohr, Y. Masaki, S. Matsui, T. Mimori, S. Nakamura, T. Nakazawa, H. Ohara, K. Okazaki, J. H. Ryu, T. Saeki, N. Schleinitz, A. Shimatsu, T. Shimosegawa, H. Takahashi, M. Takahira, A. Tanaka, M. Topazian, H. Umehara, G. J. Webster, T. E. Witzig, M. Yamamoto, W. Zhang, T. Chiba, and J. H. Stone

Idiopathic pulmonary fibrosis (IPF) is a fatal disorder without an effective therapy to date. In a double-blind, randomized, placebo-controlled trial, 107 patients were prospectively evaluated for efficacy of a novel compound, pirfenidone. The difference in the change in the lowest oxygen saturation by pulse oximetry (SpO2) during a 6-minute exercise test, the primary endpoint, from baseline to 6 months was not significant between the two groups (p = 0.0722). In a prespecified subset of patients who maintained a SpO2 greater than 80% during a 6-minute exercise test at baseline, the lowest SpO2 improved during a 6-minute exercise test in the pirfenidone group at 6 and 9 months (p = 0.0069 and 0.0305, respectively). Positive treatment effect was demonstrated in secondary endpoints: (1) change in VC measurements at 9 months (p = 0.0366) and (2) episodes of acute exacerbation of IPF occurring exclusively in the placebo group during the 9 months (p = 0.0031). Significant adverse events were associated with pirfenidone; however, adherence to treatment regimen was similar between pirfenidone and placebo groups. In conclusion, treatment with pirfenidone improved VC and prevented acute exacerbation of IPF during the 9 months of follow-up. Future long-term studies are needed to clarify the overall safety and efficacy of pirfenidone in IPF.

Reactive oxygen species (ROS), a class of highly bioactive molecules, have been widely studied in various types of cancers. ROS are considered to be normal byproducts of numerous cellular processes. Typically, cancer cells exhibit higher basal levels of ROS compared with normal cells as a result of an imbalance between oxidants and antioxidants. ROS have a dual role in cell metabolism: At low to moderate levels, ROS act as signal transducers to activate cell proliferation, migration, invasion, and angiogenesis. In contrast, high levels of ROS cause damage to proteins, nucleic acids, lipids, membranes, and organelles, leading to cell death. Extensive studies have revealed that anticancer therapies that manipulate ROS levels, including immunotherapies, show promising in vitro as well as in vivo results. In this review, we summarize molecular mechanisms and oncogenic functions that modulate ROS levels and are useful for the development of cancer therapeutic strategies. This review also provides insights into the future development of effective agents that regulate the redox system for cancer treatment.

Large-scale genomic characterization of tumors from prospective cohort studies may yield new insights into cancer pathogenesis. We performed whole-exome sequencing of 619 incident colorectal cancers (CRCs) and integrated the results with tumor immunity, pathology, and survival data. We identified recurrently mutated genes in CRC, such as BCL9L, RBM10, CTCF, and KLF5, that were not previously appreciated in this disease. Furthermore, we investigated the genomic correlates of immune-cell infiltration and found that higher neoantigen load was positively associated with overall lymphocytic infiltration, tumor-infiltrating lymphocytes (TILs), memory T cells, and CRC-specific survival. The association with TILs was evident even within microsatellite-stable tumors. We also found positive selection of mutations in HLA genes and other components of the antigen-processing machinery in TIL-rich tumors. These results may inform immunotherapeutic approaches in CRC. More generally, this study demonstrates a framework for future integrative molecular epidemiology research in colorectal and other malignancies.

This study was performed to examine the usefulness of medical endoscopic imaging utilizing narrow-band illumination. The contrast between the vascular pattern and the adjacent mucosa of the underside of the human tongue was measured using five narrow-band illuminations and three broadband illuminations. The results demonstrate that the pathological features of a vascular pattern are dependent on the center wavelength and the bandwidth of illumination. By utilizing narrow-band illumination of 415+/-30 nm, the contrast of the capillary pattern in the superficial layer was markedly improved. This is an important benefit that is difficult to obtain with ordinary broadband illumination. The appearances of capillary patterns on color images were evaluated for three sets of filters. The narrow, band imaging (NBI) filter set (415+/-30 nm, 445+/-30 nm, 500+/-30 nm) was selected to achieve the preferred appearance of the vascular patterns for clinical tests. The results of clinical tests in colonoscopy and esophagoscopy indicated that NBI will be useful as a supporting method for observation of the endoscopic findings of early cancer.

Macrophages are effector cells of the innate immune system that phagocytose bacteria and secrete both pro-inflammatory and antimicrobial mediators. In addition, macrophages play an important role in eliminating diseased and damaged cells through their programmed cell death. Generally, macrophages ingest and degrade dead cells, debris, tumor cells, and foreign materials. They promote homeostasis by responding to internal and external changes within the body, not only as phagocytes, but also through trophic, regulatory, and repair functions. Recent studies demonstrated that macrophages differentiate from hematopoietic stem cell-derived monocytes and embryonic yolk sac macrophages. The latter mainly give rise to tissue macrophages. Macrophages exist in all vertebrate tissues and have dual functions in host protection and tissue injury, which are maintained at a fine balance. Tissue macrophages have heterogeneous phenotypes in different tissue environments. In this review, we focused on the phagocytic function of macrophage-enforcing innate immunity and tissue homeostasis for a better understanding of the role of tissue macrophages in several pathological conditions.

BACKGROUND: Stereotactic irradiation (STI) has been actively performed using various methods to achieve better local control of Stage I nonsmall cell lung carcinoma (NSCLC) in Japan. The authors retrospectively evaluated results from a Japanese multiinstitutional study. METHODS: Patients with Stage I NSCLC (n = 245; median age, 76 years; T1N0M0, n = 155; T2N0M0, n = 90) were treated with hypofractionated high-dose STI in 13 institutions. Stereotactic three-dimensional treatment was performed using noncoplanar dynamic arcs or multiple static ports. A total dose of 18-75 gray (Gy) at the isocenter was administered in 1-22 fractions. The median calculated biologic effective dose (BED) was 108 Gy (range, 57-180 Gy). RESULTS: During follow-up (median, 24 months; range, 7-78 months), pulmonary complications of National Cancer Institute-Common Toxicity Criteria Grade > 2 were observed in only 6 patients (2.4%). Local progression occurred in 33 patients (14.5%), and the local recurrence rate was 8.1% for BED > or = 100 Gy compared with 26.4% for < 100 Gy (P < 0.05). The 3-year overall survival rate of medically operable patients was 88.4% for BED > or = 100 Gy compared with 69.4% for < 100 Gy (P < 0.05). CONCLUSIONS: Hypofractionated high-dose STI with BED < 150 Gy was feasible and beneficial for curative treatment of patients with Stage I NSCLC. For all treatment methods and schedules, local control and survival rates were better with BED > or = 100 Gy compared with < 100 Gy. Survival rates in selected patients (medically operable, BED > or = 100 Gy) were excellent, and were potentially comparable to those of surgery.

BACKGROUND: Regular use of aspirin after a diagnosis of colon cancer has been associated with a superior clinical outcome. Experimental evidence suggests that inhibition of prostaglandin-endoperoxide synthase 2 (PTGS2) (also known as cyclooxygenase-2) by aspirin down-regulates phosphatidylinositol 3-kinase (PI3K) signaling activity. We hypothesized that the effect of aspirin on survival and prognosis in patients with cancers characterized by mutated PIK3CA (the phosphatidylinositol-4,5-bisphosphonate 3-kinase, catalytic subunit alpha polypeptide gene) might differ from the effect among those with wild-type PIK3CA cancers. METHODS: We obtained data on 964 patients with rectal or colon cancer from the Nurses' Health Study and the Health Professionals Follow-up Study, including data on aspirin use after diagnosis and the presence or absence of PIK3CA mutation. We used a Cox proportional-hazards model to compute the multivariate hazard ratio for death. We examined tumor markers, including PTGS2, phosphorylated AKT, KRAS, BRAF, microsatellite instability, CpG island methylator phenotype, and methylation of long interspersed nucleotide element 1. RESULTS: Among patients with mutated-PIK3CA colorectal cancers, regular use of aspirin after diagnosis was associated with superior colorectal cancer-specific survival (multivariate hazard ratio for cancer-related death, 0.18; 95% confidence interval [CI], 0.06 to 0.61; P<0.001 by the log-rank test) and overall survival (multivariate hazard ratio for death from any cause, 0.54; 95% CI, 0.31 to 0.94; P=0.01 by the log-rank test). In contrast, among patients with wild-type PIK3CA, regular use of aspirin after diagnosis was not associated with colorectal cancer-specific survival (multivariate hazard ratio, 0.96; 95% CI, 0.69 to 1.32; P=0.76 by the log-rank test; P=0.009 for interaction between aspirin and PIK3CA variables) or overall survival (multivariate hazard ratio, 0.94; 95% CI, 0.75 to 1.17; P=0.96 by the log-rank test; P=0.07 for interaction). CONCLUSIONS: Regular use of aspirin after diagnosis was associated with longer survival among patients with mutated-PIK3CA colorectal cancer, but not among patients with wild-type PIK3CA cancer. The findings from this molecular pathological epidemiology study suggest that the PIK3CA mutation in colorectal cancer may serve as a predictive molecular biomarker for adjuvant aspirin therapy. (Funded by The National Institutes of Health and others.).

Prediction of clinical outcome in cancer is usually achieved by histopathological evaluation of tissue samples obtained during surgical resection of the primary tumor. Traditional tumor staging (AJCC/UICC-TNM classification) summarizes data on tumor burden (T), presence of cancer cells in draining and regional lymph nodes (N) and evidence for metastases (M). However, it is now recognized that clinical outcome can significantly vary among patients within the same stage. The current classification provides limited prognostic information, and does not predict response to therapy. Recent literature has alluded to the importance of the host immune system in controlling tumor progression. Thus, evidence supports the notion to include immunological biomarkers, implemented as a tool for the prediction of prognosis and response to therapy. Accumulating data, collected from large cohorts of human cancers, has demonstrated the impact of immune-classification, which has a prognostic value that may add to the significance of the AJCC/UICC TNM-classification. It is therefore imperative to begin to incorporate the 'Immunoscore' into traditional classification, thus providing an essential prognostic and potentially predictive tool. Introduction of this parameter as a biomarker to classify cancers, as part of routine diagnostic and prognostic assessment of tumors, will facilitate clinical decision-making including rational stratification of patient treatment. Equally, the inherent complexity of quantitative immunohistochemistry, in conjunction with protocol variation across laboratories, analysis of different immune cell types, inconsistent region selection criteria, and variable ways to quantify immune infiltration, all underline the urgent requirement to reach assay harmonization. In an effort to promote the Immunoscore in routine clinical settings, an international task force was initiated. This review represents a follow-up of the announcement of this initiative, and of the J Transl Med. editorial from January 2012. Immunophenotyping of tumors may provide crucial novel prognostic information. The results of this international validation may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune).

Several small-molecule inhibitors and monoclonal antibodies are now approved for the therapy of various cancers. Focusing on the example of the epidermal growth factor receptor inhibitors, this Review compares and contrasts these two classes of agents. The 'magic bullet' concept of specifically targeting cancer cells at the same time as sparing normal tissues is now proven, as several monoclonal antibodies and targeted small-molecule compounds have been approved for cancer treatment. Both antibodies and small-molecule compounds are therefore promising tools for target-protein-based cancer therapy. We discuss and compare the distinctive properties of these two therapeutic strategies so as to provide a better view for the development of new drugs and the future direction of cancer therapy.

Sir2 (silent information regulator 2) is an NAD+-dependent histone deacetylase that contributes to longevity in yeast. SIRT1, a mammalian Sir2 ortholog, deacetylates histones and various transcription factors, including p53, FOXO proteins, and peroxisome proliferator-activated receptor-γ. We found that its subcellular localization varied in different tissues of the adult mouse. Some subsets of neurons predominantly expressed SIRT1 in the cytoplasm, but ependymal cells expressed it in both the nucleus and cytoplasm. On the other hand, spermatocytes expressed SIRT1 only in the nucleus. Cardiomyocytes in the day 12.5 mouse embryo expressed SIRT1 exclusively in the nucleus, but in the adult heart, they expressed it in both the cytoplasm and nucleus. C2C12 myoblast cells expressed SIRT1 in the nucleus, but it localized to the cytoplasm after differentiation. LY294002, an inhibitor of phosphoinositide 3-hydroxykinase, strongly inhibited the nuclear localization of SIRT1 in undifferentiated C2C12 cells. In a heterokaryon assay, SIRT1 shuttled between the nucleus and cytoplasm, and leptomycin B, an inhibitor of CRM1-mediated nuclear exportation, inhibited this shuttling. Two nuclear localization signals and two nuclear signals and nuclear SIRT1 the of histone in C2C12 cells. only the nuclear the of C2C12 cells an that is a of SIRT1, in and in of Sir2 (silent information regulator 2) is an NAD+-dependent histone deacetylase that contributes to longevity in yeast. SIRT1, a mammalian Sir2 ortholog, deacetylates histones and various transcription factors, including p53, FOXO proteins, and peroxisome proliferator-activated receptor-γ. We found that its subcellular localization varied in different tissues of the adult mouse. Some subsets of neurons predominantly expressed SIRT1 in the cytoplasm, but ependymal cells expressed it in both the nucleus and cytoplasm. On the other hand, spermatocytes expressed SIRT1 only in the nucleus. Cardiomyocytes in the day 12.5 mouse embryo expressed SIRT1 exclusively in the nucleus, but in the adult heart, they expressed it in both the cytoplasm and nucleus. C2C12 myoblast cells expressed SIRT1 in the nucleus, but it localized to the cytoplasm after differentiation. LY294002, an inhibitor of phosphoinositide 3-hydroxykinase, strongly inhibited the nuclear localization of SIRT1 in undifferentiated C2C12 cells. In a heterokaryon assay, SIRT1 shuttled between the nucleus and cytoplasm, and leptomycin B, an inhibitor of CRM1-mediated nuclear exportation, inhibited this shuttling. Two nuclear localization signals and two nuclear signals and nuclear SIRT1 the of histone in C2C12 cells. only the nuclear the of C2C12 cells an that is a of SIRT1, in and in of Sir2 (silent information regulator 2) a of histone found in to and histone the Sir2 the In Sir2 in Sir2 the of in the and the of a of the in to and the Sir2 an in this of the Sir2 of SIRT1 is the of SIRT1 in and in peroxisome proliferator-activated SIRT1 deacetylates the transcription the of and the of SIRT1 contributes to and the of the of FOXO is SIRT1, SIRT1 the of and of SIRT1 it deacetylates and a transcription that the of myoblast cells a of SIRT1 and in various including heart, and an SIRT1 in to a nuclear it is localized exclusively to the nucleus in cells and in cells SIRT1 the localization of SIRT1 in and in the subcellular localization of Sir2 the subcellular localization of SIRT1 and in to and SIRT1 deacetylates histones and various transcription factors, its subcellular localization its of to and of the nucleus, that the of the nuclear of a is a nuclear localization nuclear localization nuclear phosphoinositide leptomycin nuclear localization nuclear phosphoinositide leptomycin in the is a of and a is the of two of a of of the nucleus is nuclear signals of is a of and the subcellular localization of a the of the In is to an in this of this that the subcellular localization of SIRT1 in various tissues and cells. the of SIRT1 in SIRT1 is to the cytoplasm the of C2C12 myoblast cells. We found that the phosphoinositide the subcellular localization of LY294002, an inhibitor of the localization of SIRT1 in C2C12 the nuclear of SIRT1 We a heterokaryon to that SIRT1 is a We two and two in SIRT1 and of nuclear SIRT1 inhibited a of the of SIRT1 to a in the of and in and in to in and in a and a to in and the and and and day mouse and in of the cells and nuclear a mammalian histone histone and and cells in of the C2C12 cells a the cells of the leptomycin cells in and its and in cells and in the cells cells to the cells in a and and the cells the of and cells in the of the the of mouse SIRT1 its the the and and the SIRT1 and the and a and cells an in of the in a in the of the of the subcellular localization of SIRT1 in adult mouse and in cells of the SIRT1 expressed in the cytoplasm and in ependymal it expressed in both the cytoplasm and nucleus On the other hand, spermatocytes and expressed SIRT1 only in We the subcellular localization of SIRT1 localized exclusively to the nucleus in the of day 12.5 In the of adult and nuclear SIRT1 the in SIRT1 subcellular of day and adult SIRT1 only in the nuclear in the In the of the in the in the nuclear in the adult and SIRT1 the nucleus to the cytoplasm in in the myoblast expressed only in the nucleus in of the cells. after of the cells expressed in the cytoplasm of SIRT1 that SIRT1 the nucleus to the cytoplasm in to the that SIRT1 a localization of and SIRT1 in C2C12 cells. of and SIRT1, nuclear and B, of and the subcellular of C2C12 cells that the of SIRT1, strongly inhibited of C2C12 after of and is heterokaryon and and and and the of cells in the and of other and the FOXO that the subcellular of SIRT1 We the of various the localization of in C2C12 cells and found that LY294002, an inhibitor of the nucleus In the nuclear of an of the to cells LY294002, in the nucleus of of of and the the of a of inhibited the of of that the subcellular localization of SIRT1 the the of SIRT1, a heterokaryon and both of SIRT1 exclusively in the nucleus. cells SIRT1 shuttled between the nucleus and the cytoplasm in the found only in the nucleus, but in the nucleus. in in that in of the the cells it the nucleus the heterokaryon a of the the of an and this is inhibited inhibited the of the nucleus to the nucleus in the of in its p53, a the nuclear of the of that nuclear that SIRT1 is an of the in the nucleus. We the of SIRT1 to of a of Two found in and to and and a of and expressed in cells and the both and and expressed exclusively in the nucleus and the of and and in the of the to both the cytoplasm and nucleus. both and the localized to the cytoplasm that both and and that the nuclear localization of the both of the the SIRT1 of the to the the of and cells the after the cells and B, of and of the the and the and and cells the and and in the two in and to a that to the nucleus and cytoplasm the in to an of to the cytoplasm and nucleus of and in the localization of the both and in the nuclear of of the in inhibited the nuclear of SIRT1 SIRT1 is to an of a the of the in SIRT1, of and cells SIRT1 that the two exclusively nuclear localization it to the of an only nuclear both the SIRT1 of the to the B, cells the in after the cells and of cells in the nucleus in both the nucleus and cytoplasm and in the cytoplasm cells of and and the of in cells in in this of in subcellular the of cells in the nucleus in both the nucleus and cytoplasm, and in the cytoplasm and the of in the of cells the of SIRT1 and subcellular of the cells the in the cytoplasm in the cytoplasm in that the nuclear of this is an a subcellular to an is in the of the expressed in the cytoplasm in of the cells In expressed in the cytoplasm and that between and of the and of and to and and the of the of and and the of cells that expressed in the nucleus to and to In the of cells in the cytoplasm to and to and that both and of and in of of the of and and and the B, of the the and and cells the and in of cells in the nucleus in both the nucleus and cytoplasm and in the cytoplasm cells of and and the the of in nuclear in in nuclear in the nuclear of and and and the of cells the in the cytoplasm to a and the of to and that both and nuclear and the nuclear the heterokaryon cells cells of the expressed the in the of the nuclear of the the In only of the that that nuclear the in and the nuclear only of the that of the the heterokaryon of the of the and and and and B, of the the and the and cells cells that and and and in the of cells nuclear in a and but in and of the of the of the of SIRT1, and in the nucleus and cytoplasm, expressed in C2C12 cells the of the deacetylase of SIRT1, a SIRT1 in the nucleus deacetylase of SIRT1 and its that and histone of nuclear SIRT1 the of histone the other and the of histone of SIRT1 the of and histone in the C2C12 cells that only nuclear SIRT1 histone of the nuclear of C2C12 cells a a of SIRT1 after the cells and and and and in the cells of and cells the but B, of cells cells and the in in the after that strongly inhibited the and of of histone nuclear C2C12 myoblast cells a a of SIRT1 and the histone the of histone histone of histone and and histone of histone the cells an inhibitor of and histone in to We the of the subcellular localization and of SIRT1 the in C2C12 cells of the and the of C2C12 cells and and the cells the the of that only of the cells the the this of nuclear SIRT1 the of the the to of that and this the of nuclear SIRT1 SIRT1 in in the cells of the the cells the SIRT1 a only nuclear SIRT1 a in C2C12 subcellular localization of SIRT1 to in cells nuclear of SIRT1, but expressed it in the cytoplasm in both the nucleus and cytoplasm. subcellular localization of SIRT1 two and two in its and the We found that only nuclear SIRT1 in histone and the Sir2 to its subcellular localization it is expressed in both the cytoplasm and it to the cytoplasm and it is to in both We found that Sir2 two in and and in a and and the of Sir2 and to that of in mouse SIRT1, Sir2 only two but that to and of mouse the of Sir2 a that is to this the of the of the that both the heterokaryon that only the nuclear that in SIRT1, but it the of a of localization of SIRT1 that the is in C2C12 cells. In found that in C2C12 cells of in the of that of and its to nuclear in the of two that nuclear SIRT1 the in C2C12 myoblast cells in the nuclear of SIRT1 an in and is in SIRT1 the nucleus and in SIRT1 cells in this is the SIRT1 is to and p53, in the of in cells in the of SIRT1 the of the the of of nuclear SIRT1 cells and and the nucleus, in SIRT1 to the of FOXO it is that SIRT1 and FOXO an found that the of SIRT1 that of FOXO a a transcription in the nucleus and it is is its nuclear localization both and other and of the localization of SIRT1 is of histone transcription that histone nuclear of SIRT1 and its localization to the of transcription SIRT1 to and a transcription the of SIRT1 the nucleus the of in differentiation. that SIRT1 the nucleus the of C2C12 cells is in this the of SIRT1 a its the nuclear of SIRT1 the to of the of SIRT1 to its nuclear a Sir2 (silent information regulator 2) a of histone found in to and histone the Sir2 the In Sir2 in Sir2 the of in the and the of a of the in to and the Sir2 an in this In of the Sir2 of SIRT1 is the of SIRT1 in and in peroxisome proliferator-activated SIRT1 deacetylates the transcription the of and the of SIRT1 contributes to and the of the of FOXO is SIRT1, SIRT1 the of and of SIRT1 it deacetylates and a transcription that the of myoblast cells a of SIRT1 and in various including heart, and an SIRT1 in differentiation. SIRT1 to a nuclear it is localized exclusively to the nucleus in cells and in cells SIRT1 the localization of SIRT1 in and in the subcellular localization of Sir2 the subcellular localization of SIRT1 and in to and SIRT1 deacetylates histones and various transcription factors, its subcellular localization its of to and of the nucleus, that the of the nuclear of a is a nuclear localization nuclear localization nuclear phosphoinositide leptomycin nuclear localization nuclear phosphoinositide leptomycin in the is a of and a is the of two of a of of the nucleus is nuclear signals of is a of and the subcellular localization of a the of the In is to an in this of In this that the subcellular localization of SIRT1 in various tissues and cells. the of SIRT1 in SIRT1 is to the cytoplasm the of C2C12 myoblast cells. We found that the phosphoinositide the subcellular localization of LY294002, an inhibitor of the localization of SIRT1 in C2C12 the nuclear of SIRT1 We a heterokaryon to that SIRT1 is a We two and two in SIRT1 and of nuclear SIRT1 inhibited a of the of SIRT1 to a in the of and in and in to in and in a and a to in and the and and and day mouse and in of the cells and nuclear a mammalian histone histone and and cells in of the C2C12 cells a the cells of the leptomycin cells in and its and in cells and in the cells cells to the cells in a and and the cells the of and cells in the of the the of mouse SIRT1 its the the and and the SIRT1 and the and a and cells an in of the in a in the of the and in and in to in and in a and a to in and the and and and day mouse and in of the cells and nuclear a mammalian histone histone and and cells in of the C2C12 cells a the cells of the leptomycin cells in and its and in cells and in the cells cells to the cells in a and and the cells the of and cells in the of the the of mouse SIRT1 its the the and and the SIRT1 and the and a and cells an in of the in a in the of the of the subcellular localization of SIRT1 in adult mouse and in cells of the SIRT1 expressed in the cytoplasm and in ependymal it expressed in both the cytoplasm and nucleus On the other hand, spermatocytes and expressed SIRT1 only in We the subcellular localization of SIRT1 localized exclusively to the nucleus in the of day 12.5 In the of adult and nuclear SIRT1 the in SIRT1 subcellular of day and adult SIRT1 only in the nuclear in the In the of the in the in the nuclear in the adult and SIRT1 the nucleus to the cytoplasm in in the myoblast expressed only in the nucleus in of the cells. after of the cells expressed in the cytoplasm of SIRT1 that SIRT1 the nucleus to the cytoplasm in to the that SIRT1 a other and the FOXO that the subcellular of SIRT1 We the of various the localization of in C2C12 cells and found that LY294002, an inhibitor of the nucleus In the nuclear of an of the to cells LY294002, in the nucleus of of of and the the of a of inhibited the of of that the subcellular localization of SIRT1 the the of SIRT1, a heterokaryon and both of SIRT1 exclusively in the nucleus. cells SIRT1 shuttled between the nucleus and the cytoplasm in the found only in the nucleus, but in the nucleus. in in that in of the the cells it the nucleus the heterokaryon a of the the of an and this is inhibited inhibited the of the nucleus to the nucleus in the of in its p53, a the nuclear of the of that nuclear that SIRT1 is an of the in the nucleus. We the of SIRT1 to of a of Two found in and to and and a of and expressed in cells and the both and and expressed exclusively in the nucleus and the of and and in the of the to both the cytoplasm and nucleus. both and the localized to the cytoplasm that both and and that the nuclear localization of the both of the the SIRT1 of the to the the of and cells the after the cells and B, of and of the the and the and and cells the and and in the two in and to a that to the nucleus and cytoplasm the in to an of to the cytoplasm and nucleus of and in the localization of the both and in the nuclear of of the in inhibited the nuclear of SIRT1 SIRT1 is to an of a the of the in SIRT1, of and cells SIRT1 that the two exclusively nuclear localization it to the of an only nuclear both the SIRT1 of the to the B, cells the in after the cells and of cells in the nucleus in both the nucleus and cytoplasm and in the cytoplasm cells of and and the of in cells in in this of in subcellular the of cells in the nucleus in both the nucleus and cytoplasm, and in the cytoplasm and the of in the of cells the of SIRT1 and subcellular of the cells the in the cytoplasm in the cytoplasm in that the nuclear of this is an a subcellular to an is in the of the expressed in the cytoplasm in of the cells In expressed in the cytoplasm and that between and of the and of and to and and the of the of and and the of cells that expressed in the nucleus to and to In the of cells in the cytoplasm to and to and that both and of and in of of the of and and and the B, of the the and and cells the and in of cells in the nucleus in both the nucleus and cytoplasm and in the cytoplasm cells of and and the the of in nuclear in in nuclear in the nuclear of and and and the of cells the in the cytoplasm to a and the of to and that both and nuclear and the nuclear the heterokaryon cells cells of the expressed the in the of the nuclear of the the In only of the that that nuclear the in and the nuclear only of the that of the the heterokaryon of the of the and and and and B, of the the and the and cells cells that and and and in the of cells nuclear in a and but in and of the of the of the of SIRT1, and in the nucleus and cytoplasm, expressed in C2C12 cells the of the deacetylase of SIRT1, a SIRT1 in the nucleus deacetylase of SIRT1 and its that and histone of nuclear SIRT1 the of histone the other and the of histone of SIRT1 the of and histone in the C2C12 cells that only nuclear SIRT1 histone of the nuclear of C2C12 cells a a of SIRT1 after the cells and and and and in the cells of and cells the but B, of cells cells and the in in the after that strongly inhibited the and of of histone nuclear C2C12 myoblast cells a a of SIRT1 and the histone the of histone histone of histone and and histone of histone the cells an inhibitor of and histone in to We the of the subcellular localization and of SIRT1 the in C2C12 cells of the and the of C2C12 cells and and the cells the the of that only of the cells the the this of nuclear SIRT1 the of the the to of that and this the of nuclear SIRT1 SIRT1 in in the cells of the the cells the SIRT1 a only nuclear SIRT1 a in C2C12 cells. of the subcellular localization of SIRT1 in adult mouse and in cells of the SIRT1 expressed in the cytoplasm and in ependymal it expressed in both the cytoplasm and nucleus On the other hand, spermatocytes and expressed SIRT1 only in We the subcellular localization of SIRT1 localized exclusively to the nucleus in the of day 12.5 In the of adult and nuclear SIRT1 the in SIRT1 subcellular of day and adult SIRT1 only in the nuclear in the In the of the in the in the nuclear in the adult and We SIRT1 the nucleus to the cytoplasm in in the myoblast expressed only in the nucleus in of the cells. after of the cells expressed in the cytoplasm of SIRT1 that SIRT1 the nucleus to the cytoplasm in to the that SIRT1 a other and the FOXO that the subcellular of SIRT1 We the of various the localization of in C2C12 cells and found that LY294002, an inhibitor of the nucleus In the nuclear of an of the to cells LY294002, in the nucleus of of of and the the of a of inhibited the of of that the subcellular localization of SIRT1 the the of SIRT1, a heterokaryon and both of SIRT1 exclusively in the nucleus. cells SIRT1 shuttled between the nucleus and the cytoplasm in the found only in the nucleus, but in the nucleus. in in that in of the the cells it the nucleus the heterokaryon cytoplasm. a of the the of an and this is inhibited inhibited the of the nucleus to the nucleus in the of in its p53, a the nuclear of the of that nuclear that SIRT1 is an of the in the nucleus. We the of SIRT1 to of a of Two found in and to and and a of and expressed in cells and the both and and expressed exclusively in the nucleus and the of and and in the of the to both the cytoplasm and nucleus. both and the localized to the cytoplasm that both and and that the nuclear localization of the both We in the two in and to a that to the nucleus and cytoplasm the in to an of to the cytoplasm and nucleus of and in the localization of the both and in the nuclear of of the in inhibited the nuclear of SIRT1 SIRT1 is to an of a the of the in SIRT1, of and cells SIRT1 that the two exclusively nuclear localization it to the of an only nuclear both In this of in subcellular the of cells in the nucleus in both the nucleus and cytoplasm, and in the cytoplasm and the of in the of cells the of SIRT1 and subcellular of the cells the in the cytoplasm in the cytoplasm in that the nuclear of this is an a subcellular to an We is in the of the expressed in the cytoplasm in of the cells In expressed in the cytoplasm and that between and of the and of and to and and the of the of and and the of cells that expressed in the nucleus to and to In the of cells in the cytoplasm to and to and that both and the nuclear of and and and the of cells the in the cytoplasm to a and the of to and that both and nuclear We and the nuclear the heterokaryon cells cells of the expressed the in the of the nuclear of the the In only of the that that nuclear the in and the nuclear only of the that of the of the of the of SIRT1, and in the nucleus and cytoplasm, expressed in C2C12 cells the of the deacetylase of SIRT1, a SIRT1 in the nucleus deacetylase of SIRT1 and its that and histone of nuclear SIRT1 the of histone the other and the of histone of SIRT1 the of and histone in the C2C12 cells that only nuclear SIRT1 histone SIRT1 in to We the of the subcellular localization and of SIRT1 the in C2C12 cells of the and the of C2C12 cells and and the cells the the of that only of the cells the the this of nuclear SIRT1 the of the the to of that and this the of nuclear SIRT1 SIRT1 in in the cells of the the cells the SIRT1 a only nuclear SIRT1 a in C2C12 cells. subcellular localization of SIRT1 to in cells nuclear of SIRT1, but expressed it in the cytoplasm in both the nucleus and cytoplasm. subcellular localization of SIRT1 two and two in its and the We found that only nuclear SIRT1 in histone and the Sir2 to its subcellular localization it is expressed in both the cytoplasm and it to the cytoplasm and it is to in both We found that Sir2 two in and and in a and and the of Sir2 and to that of in mouse SIRT1, Sir2 only two but that to and of mouse the of Sir2 a that is to this the of the of the that both the heterokaryon that only the nuclear that in SIRT1, but it the of a of localization of SIRT1 that the is in C2C12 cells. In found that in C2C12 cells of in the of that of and its to nuclear in the of two that nuclear SIRT1 the in C2C12 myoblast cells in the nuclear of SIRT1 an in and is in SIRT1 the nucleus and in SIRT1 cells in this is the SIRT1 is to and p53, in the of in cells in the of SIRT1 the of the the of of nuclear SIRT1 cells and and the nucleus, in SIRT1 to the of FOXO it is that SIRT1 and FOXO an found that the of SIRT1 that of FOXO a a transcription in the nucleus and it is is its nuclear localization both and other and of the localization of SIRT1 is of histone transcription that histone nuclear of SIRT1 and its localization to the of transcription SIRT1 to and a transcription the of SIRT1 the nucleus the of in differentiation. that SIRT1 the nucleus the of C2C12 cells is in this the of SIRT1 a its the nuclear of SIRT1 the to of the of SIRT1 to its nuclear a subcellular localization of SIRT1 to in cells nuclear of SIRT1, but expressed it in the cytoplasm in both the nucleus and cytoplasm. subcellular localization of SIRT1 two and two in its and the We found that only nuclear SIRT1 in histone and the Sir2 to its subcellular localization it is expressed in both the cytoplasm and it to the cytoplasm and it is to in both We found that Sir2 two in and and in a and and the of Sir2 and to that of in mouse SIRT1, Sir2 only two but that to and of mouse the of Sir2 a that is to yeast. In this the of the of the that both the heterokaryon that only the nuclear that in SIRT1, but it the of a of localization of SIRT1 that the is in C2C12 cells. In found that in C2C12 cells of in the of that of and its to nuclear in the of two We that nuclear SIRT1 the in C2C12 myoblast cells in the nuclear of SIRT1 an in and is in SIRT1 the nucleus and in SIRT1 cells in this is the SIRT1 is to and p53, in the of in cells in the of SIRT1 the of the the of of nuclear SIRT1 cells and and the nucleus, in SIRT1 to the of FOXO it is that SIRT1 and FOXO an found that the of SIRT1 that of FOXO a a transcription in the nucleus and it is is its nuclear localization both and other and of the localization of SIRT1 is of histone transcription that histone nuclear of SIRT1 and its localization to the of transcription SIRT1 to and a transcription the of SIRT1 the nucleus the of in differentiation. that SIRT1 the nucleus the of C2C12 cells is in this In the of SIRT1 a its the nuclear of SIRT1 the to of the of SIRT1 to its nuclear a

John H. Stone, Arezou Khosroshahi, Vikram Deshpande, John K. C. Chan, J. Godfrey Heathcote, Rob Aalberse, Atsushi Azumi, Donald B. Bloch, William R. Brugge, Mollie N. Carruthers, Wah Cheuk, Lynn Cornell, Carlos Fernandez-Del Castillo, Judith A. Ferry, David Forcione, Gunter Kloppel, Daniel L. Hamilos, Terumi Kamisawa, Satomi Kasashima, Shigeyuki Kawa, Mitsuhiro Kawano, Yasufumi Masaki, Kenji Notohara, Kazuichi Okazaki, Ji Kon Ryu, Takako Saeki, Dushyant Sahani, Yasuharu Sato, Thomas Smyrk, James R. Stone, Masayuki Takahira, Hisanori Umehara, George Webster, Motohisa Yamamoto, Eunhee Yi, Tadashi Yoshino, Giuseppe Zamboni, Yoh Zen, and Suresh Chari